The influence of SARS‐CoV‐2 infection on expression of drug‐metabolizing enzymes and transporters in a hACE2 murine model
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and the resulting Coronavirus disease 2019 emerged in late 2019 and is responsible for significant morbidity and mortality worldwide. A hallmark of severe COVID‐19 is exaggerated systemic inflammation, regarded as a “cyt...
Main Authors: | Kiran Deshpande, Keith R. Lange, William B. Stone, Christine Yohn, Naomi Schlesinger, Leonid Kagan, Albert J. Auguste, Bonnie L. Firestein, Luigi Brunetti |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-06-01
|
Series: | Pharmacology Research & Perspectives |
Subjects: | |
Online Access: | https://doi.org/10.1002/prp2.1071 |
Similar Items
-
Neuropathological lesions in intravenous BCG-stimulated K18-hACE2 mice challenged with SARS-CoV-2
by: Lidia Sánchez-Morales, et al.
Published: (2024-05-01) -
Molecular Docking and Dynamics Simulation Revealed the Potential Inhibitory Activity of ACEIs Against SARS-CoV-2 Targeting the hACE2 Receptor
by: Ahmed A. Al-Karmalawy, et al.
Published: (2021-05-01) -
Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice
by: Pratima Kumari, et al.
Published: (2021-01-01) -
Two new and effective food-extracted immunomodulatory agents exhibit anti-inflammatory response activity in the hACE2 acute lung injury murine model of COVID-19
by: Shasha Liu, et al.
Published: (2024-05-01) -
A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration
by: Xilin Wu, et al.
Published: (2021-10-01)